Skip to content
ENCEFA logo — ENCEFA, a longevity company that reprogram suffering cells a...

ENCEFA

ENCEFA, a longevity company that reprogram suffering cells and activated immune cells

Founded 2016 France France 1 employees Seed Total: $250.00K Biotechnology, Health and Wellness +2

General Information

Company Name ENCEFA
Founded Year 2016
Location France France
Employees 1
Industries Biotechnology, Health and Wellness, Life Sciences +1
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with ENCEFA. To contact ENCEFA, visit encefa.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ENCEFA compare?

A PDF of ENCEFA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ENCEFA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ENCEFA

ENCEFA, founded in 2016 and headquartered in France, is a biotechnology company pioneering cell rejuvenation therapies for age-related diseases. Their innovative approach involves developing novel CD38 modulators that enhance cellular autophagy and energy metabolism, addressing cellular senescence—a key component in aging.

Their recent work has led to the discovery of a biological pathway where CD38 is utilized in a unique way, a breakthrough protected by three patents. This method resembles a natural rescue mechanism impaired during aging, leading to increased NAD+ levels and improved cellular function. Their flagship product, NC-B8, is a revolutionary brain-penetrant antibody aimed at neurodegenerative conditions like Amyotrophic Lateral Sclerosis (ALS). Concurrently, NC-P7 is designed to protect vital organs, such as the heart and kidneys, against age-related metabolic issues.

As demonstrated in preclinical trials involving mice, rats, and dogs, ENCEFA's products show promise in rejuvenating organs and minimizing inflammation in pathological contexts. Their last investment was a $250,000 Seed Round on 30 December 2021, led by Newchip Accelerator, highlighting investor interest in their potential to transform longevity treatment.

Business keywords: Longevity, CD38 Modulators, Anti-aging Biotechnology, Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis (ALS), Metabolic Disorders, Immune System Rejuvenation, NAD+ Levels Boost, Intracellular Clearance Activation, Energy Metabolism Enhancement, Organ Protection, Biopharmaceuticals, Autophagy-Lysosomal Flux Activation, Inflammation Repair, Tissue Protection

Services & Products

development and offering of online slot games
bonus and loyalty programs
game optimization for mobile devices

Target Customers

online gamblers slot machine enthusiasts mobile gamers players seeking high RTP and jackpots loyalty program participants

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $250.00K 1
Newchip Accelerator
30 Dec 2021

ENCEFA Alternatives & Competitors

View All Alternatives
ENCEFA vs
REGENXBIO
REGENXBIO United States

Seeking to improve lives through the curative potential of gene therapy.

IPO
389 employees
Biopharma, Biotechnology
ENCEFA vs
Mimio Health
Mimio Health United States

Harness your biology with clinically-validated biomimetic cell care. Nature designed. Mimio delivere...

Seed
4 employees
Biotechnology, Health Care
ENCEFA vs

Leading the way in lysosomal ion channel biology to address neurodegenerative diseases and metabolic...

Grant
7 employees
Biotechnology, Health and Wellness

FAQ About ENCEFA

ENCEFA, a longevity company that reprogram suffering cells and activated immune cells
ENCEFA was founded in 2016.
ENCEFA is headquartered in France.
ENCEFA operates in Biotechnology, Health and Wellness, Life Sciences and Pharmaceutical. Its work centres on Longevity, CD38 Modulators, Anti-aging Biotechnology and Neurodegenerative Diseases. Its customers include online gamblers, slot machine enthusiasts and mobile gamers.
ENCEFA has approximately 1 employees.
ENCEFA has completed 1 funding round, raising a total of $250.00K. The latest funding stage is Seed.
ENCEFA offers: development and offering of online slot games, bonus and loyalty programs, game optimization for mobile devices.
Top alternatives and competitors to ENCEFA include REGENXBIO, Mimio Health, Lysoway Therapeutics, Rejuvenate Bio, Refoxy Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ENCEFA and REGENXBIO are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ENCEFA, https://bouncewatch.com/company/encefa, updated 3 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout